Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems

Scientific Reports

Article

Peng Zhang¹  Jianye Wang²  Zijian Tian²  Lingfeng Meng²  Yaoguang Zhang²  Yong Zhang³  Limin Liao⁴  Guoqing Chen⁴  Xiaojun Tian⁵  Lulin Ma⁵  Benkang Shi⁶  Yan Li⁶  Jiayi Li⁷  Zhongqing Wei⁸  Tie Zhong⁹  Qing Ling^1,10  Deyi Luo^1,11  Zhihui Xu^1,12 

[1] Department of Urology, Beijing Chaoyang Hospital, Institute of Urology, Capital Medical University, Beijing, China;Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Da Hua Road, Dong Dan, 100730, Beijing, China;Beijing Hospital Continence Center, Beijing, China;Department of Urology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;Department of Urology, China Rehabilitation Research Centre, Rehabilitation School of Capital Medical University, Beijing, China;Department of Urology, Peking University Third Hospital, Beijing, China;Department of Urology, Qilu Hospital, Shandong University, Jinan, China;Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China;Department of Urology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China;Department of Urology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China;Department of Urology, West China Hospital, Sichuan University, Chengdu, China;Department of Urology, Zhejiang Provincial People’s Hospital, Hangzhou, China;

DOI  :  10.1038/s41598-022-26267-y

 received in 2022-01-20, accepted in 2022-12-13,  发布年份 2022

来源: Springer

【 摘 要 】

This study aimed to evaluate differences in the clinical outcomes of different sacral neuromodulation systems (InterStim and BetterStim) used in the treatment of overactive bladder. Data from a previously established database of sacral neuromodulation in China (the InterStim system) and a 2020 clinical trial of the BetterStim system were screened. Patients with overactive bladder undergoing stage II implanted pulse generator implantation were selected for analysis and divided into InterStim and BetterStim system groups. Voiding diaries and subjective scores obtained preoperatively, after stage I tined-lead implantation (experience period), and after stage II implanted pulse generator implantation were compared between the two groups. This study included 113 patients with overactive bladder (43, InterStim system group; 70, BetterStim system group). Voiding diaries and subjective scores significantly improved in both the InterStim and BetterStim system groups over the treatment period. Specifically, the urination frequency (all P < 0.001), average voiding volume (all P < 0.001), and average urinary leakage (InterStim, P < 0.05; BetterStim, P < 0.01) in both groups significantly improved at different periods during treatment. At the same time, the urgency perception scale (P < 0.001) and OAB-related quality of life score (InterStim, P < 0.05; BetterStim, P < 0.01) also significantly improved. There was no significant difference in urination frequency at baseline between the two groups (P = 0.169). Urination frequency was significantly higher in the BetterStim system group than in the InterStim group during the experience period and at follow-up (P = 0.031, P = 0.006). There was no significant difference in the number of urinary leakages between the different systems at baseline (P = 0.662), although this was higher in the InterStim system group during the experience period (P = 0.016), and the difference disappeared at the last follow-up (P = 0.565). There were significant differences in baseline urgency perception scale (P = 0.001) and OAB-related quality of life score (P < 0.001) between the two groups; however, these differences were not maintained at follow-up (P = 0.81, P = 0.479). Both sacral neuromodulation systems are safe and effective in treating overactive bladder. The InterStim system may be more beneficial for patients with dry overactive bladder. Satisfactory outcomes may be achieved with the BetterStim system in patients with wet overactive bladder. However, further studies are required to confirm this finding.

【 授权许可】

CC BY   
© The Author(s) 2022